ACPMP Medical Advisory Board: Dr. Lambert Named Chair; Dr. Misdraji and Dr. Switzer Join

INDEPENDENCE, Ohio - Feb. 22, 2019 - PRLog -- The Appendix Cancer / Pseudomyxoma Peritonei Research Foundation (ACPMP) is delighted to announce that Laura Lambert, MD, FACS has been appointed Chair of the ACPMP Medical Advisory Board.  ACPMP is also pleased to welcome Joseph Misdraji, MD and Bradley Switzer, MD to the ACPMP Medical Advisory Board.

Dr. Lambert has been a member of the ACPMP Medical Advisory Board since its inception and has been a tireless champion of both the organization and the patients it serves over the past ten years.  ACPMP is thrilled that Dr. Lambert has agreed to take on this leadership role, and we look forward to continuing our joint efforts to improve the lives of appendix cancer and PMP patients worldwide.

Dr. Misdraji is the Director of the Gastrointestinal Pathology Unit in the Department of Pathology at Massachusetts General Hospital. His primary clinical interests are gastrointestinal and hepatic diseases and cytopathology. Dr. Misdraji's research interests are focused on liver pathology, gastrointestinal diseases, and appendiceal neoplasia.  Dr. Misdraji has published over 50 research papers and his research interests include appendiceal neoplasms, hepatic diseases and gastrointestinal diseases.

Dr. Switzer is the Chief of Hematology/Oncology at Reliant Medical Group in Worcester, MA and an Assistant Professor at the University of Massachusetts Medical School. Dr. Switzer's primary expertise is in treating cancer of the bowel, appendix, liver and other internal organs.  Dr. Switzer is the primary investigator on a phase I clinical trial looking at the role of intraperitoneal oxaliplatin given in combination with intravenous FOLFIRI for appendiceal cancer patients who are not surgical candidates.

Congratulations to Dr. Lambert, welcome Dr. Misdraji and Dr. Switzer, and thanks to the entire ACPMP Medical Advisory Board for their time and support!

The Appendix Cancer / Pseudomyxoma Peritonei Research Foundation (ACPMP)  is an IRS-designated 501(c)3 charitable organization (EIN: 26-2890160). The Foundation was created in 2008 by a community of individuals affected by Pseudomyxoma Peritonei (PMP), Appendix Cancer, and related Peritoneal Surface Malignancies (PSM). ACPMP is dedicated to (1) funding research to find a cure for Pseudomyxoma Peritonei (PMP), Appendix Cancer, and related Peritoneal Surface Malignancies (PSM), and (2) funding educational programs to educate physicians and patients about these diseases. For more information, visit http://www.acpmp.org.